-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Adolescents (12-17 years)
-
Hospital
-
Intensive care unit
-
Respiratory syncytial virus
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
General population
-
Infants (<1 year)
-
Hospital
-
Respiratory syncytial virus
-
Non pharmacological intervention
-
Lung ultrasound
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Hospital
-
Emergency department
-
Respiratory syncytial virus
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Respiratory syncytial virus
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Respiratory syncytial virus
-
General population
-
Infants (<1 year)
-
Hospital
-
Respiratory syncytial virus
-
Pharmacological intervention
-
Monoclonal antibodies
-
Nirsevimab